September 30, 2008
In a blow to AstraZeneca Pharmaceuticals LP and Bristol-Myers Squibb Co., a federal judge has given the green light to two national classes in the multidistrict litigation over average wholesale drug prices, allowing the plaintiffs to pursue their claims of unfair and deceptive trade practices against the two drug giants.
August 26, 2008
A class of plaintiffs asked a judge on Monday to stop Bristol-Myers Squibb Co. from modifying a distribution agreement that is part of a $13 million deal the drugmaker reached in a bid to settle a class action brought by patients who said they paid too much for their drugs.
December 20, 2007
The plaintiffs in the massive multidistrict litigation over average wholesale drug prices told a district judge on Wednesday that they are appealing her November order in the case, which let two of four defendants off the hook without damages.
December 11, 2007
Making good on its threat, AstraZeneca Pharmaceuticals LP has mounted an appeal against a federal judge's order that it fork over $12.9 million to Massachusetts plaintiffs in the massive multidistrict litigation over average wholesale drug prices.
November 06, 2007
A federal judge has ordered AstraZeneca and Bristol-Myers Squibb to pay Massachusetts plaintiffs in the average wholesale drug price multidistrict litigation $12.9 million and $695,594, respectively, doubling the damages requested after finding that the drug companies knowingly and willfully inflated the average wholesale prices for specific drugs.
October 09, 2007
Iowa has become the latest state to sue the major pharmaceutical companies for fraud, alleging that drug makers fleeced millions of dollars from taxpayers by inflating average wholesale prices used to calculate government rebates.
September 10, 2007
French drug giant Sanofi-Aventis will hand over more than $190 million to settle claims by the U.S. Department of Justice and various states that its predecessor defrauded Medicare by inflating the reported average wholesale price of a cancer drug.
August 21, 2007
Johnson & Johnson has rejected a bid by plaintiffs in the massive antitrust class action over the alleged artificial inflation of the prices of various prescription medications to decide whether to grant treble damages and attorneys' fees before entering a final judgment, arguing that it is “entitled to finality.”
August 20, 2007
Drug makers in the massive antitrust class action over the alleged artificial inflation of the prices of various prescription medications have called for mediation in the case, despite recent criticism from the attorneys general of five states.
August 17, 2007
In the wake of a June ruling that AstraZeneca, Bristol-Myers Squibb and Schering-Plough Corp. inflated average wholesale prices of drugs, plaintiffs have asked the court to decide whether to grant treble damages and attorneys' fees before entering a final judgment.